Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 4—April 2019
Research

Middle East Respiratory Syndrome Coronavirus Infection Dynamics and Antibody Responses among Clinically Diverse Patients, Saudi Arabia

Hail M. Al-Abdely1, Claire M. Midgley1Comments to Author , Abdulrahim M. Alkhamis, Glen R. Abedi, Xiaoyan Lu, Alison M. Binder, Khalid H. Alanazi, Azaibi Tamin, Weam M. Banjar, Sandra Lester, Osman Abdalla, Rebecca M. Dahl, Mutaz Mohammed, Suvang Trivedi, Homoud S. Algarni, Senthilkumar K. Sakthivel, Abdullah Algwizani, Fahad Bafaqeeh, Abdullah Alzahrani, Ali Abraheem Alsharef, Raafat F. Alhakeem, Hani A. Aziz Jokhdar, Sameeh S. Ghazal, Natalie J. Thornburg, Dean D. Erdman, Abdullah M. Assiri, John T. WatsonComments to Author , and Susan I. Gerber
Author affiliations: Ministry of Health, Riyadh, Saudi Arabia (H.M. Al-Abdely, A.M. Alkhamis, K.H. Alanazi, W.M. Banjar, O. Abdalla, M. Mohammed, H.S. Algarni, A. Alzahrani, A.A. Alsharef, R.F. Alhakeem, H.A.A. Jokhdar, A.M. Assiri); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (C.M. Midgley, G.R. Abedi, X. Lu, A.M. Binder, A. Tamin, S. Lester, R.M. Dahl, S.K. Sakthivel, N.J. Thornburg, D.D. Erdman, J.T. Watson, S.I. Gerber); Princess Nourah Bint Abdulrahman University, Riyadh (W.M. Banjar); Prince Mohammed Bin Abdulaziz Hospital, Riyadh (A. Algwizani, F. Bafaqeeh, S.S. Ghazal)

Main Article

Table 3

Clinical features of survivors with prolonged MERS-CoV detection, Saudi Arabia, August 1, 2015–August 31, 2016*

Clinical feature
 Total, N = 19
 Days to negativity
 p value†
<11 d, n = 11
 >11 d, n = 8
Symptoms before admission‡
No symptoms 4/18 (21) 3/10 (30) 1/8 (13) 0.603
Fever 13/18 (72) 7/10 (70) 6/8 (75) 1.000
Cough 11/18 (61) 5/10 (50) 6/8 (75) 0.367
Dyspnea 6/18 (33) 2/10 (20) 4/8 (50) 0.321
Vomiting 5/18 (28) 2/10 (20) 3/8 (38) 0.608
Diarrhea
 3/18 (17)
 0/10
 3/8 (38)
 0.069
Clinical course‡
Room air 13/18 (72) 9/10 (90) 4/8 (50) 0.118
Ventilator support§ 5/18 (28) 1/10 (10) 4/8 (50)
Abnormal chest radiograph
 9/18 (50)
 4/10 (40)
 5/8 (63)
 0.637
Medications¶
Ribavirin plus peg-IFNα 2/19 (11) 0/11 2/8 (25) 0.164
Oseltamivir 12/19 (63) 6/11 (55) 6/8 (75) 0.633
Antibiotics 15/19 (79) 8/11 (73) 7/8 (88) 0.603
Parenteral steroids 3/19 (16) 0/11 3/8 (38) 0.058
Group 2 only# 3/5 (60) 0/1 3/4 (75) 0.400
Inhaled steroids 2/19 (11) 0/11 2/8 (25) 0.164
Group 2 only# 2/5 (40) 0/1 2/4 (50) 1.000
Bronchodilators 5/19 (26) 2/11 (18) 3/8 (38) 0.603
Antipyretics 9/19 (47) 6/11 (55) 3/8 (38) 0.650

*Values are no. (%) patients except as indicated. Group 2, ventilated but survived; MERS-CoV, Middle East respiratory syndrome coronavirus.
†p values are for Fisher exact or Kruskall–Wallis tests comparing long-term and short-term.
‡Excludes patient no. 30, who was admitted and intubated before onset because of injuries sustained in a road traffic accident (N = 18).
§Includes mechanical or nonmechanical (i.e., bi-level positive airway pressure) ventilation.
¶Medication given during MERS-CoV detection period (on the basis of diagnostic testing in respiratory specimens).
#Assessing steroid use among G2 patients only.

Main Article

1These first authors contributed equally to this article.

Page created: March 18, 2019
Page updated: March 18, 2019
Page reviewed: March 18, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external